Phyllis C. Tien
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Phyllis C. Tien has a total of 335 co-authors. Here are the top co-authors by number of shared publications:
Yifei Ma
University of California
7 shared publications- Anandi N. Sheth
Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
6 shared publications Anjali Sharma
Department of Medicine, Albert Einstein College of Medicine , Bronx, New York, USA
6 shared publications- Deborah Konkle-Parker
Schools of Nursing, Medicine, and Population Health Sciences, University of Mississippi Medical Center , Jackson, Mississippi
5 shared publications - Igho Ofotokun
Division of Infectious Disease, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia (I.O., Z.W.)
5 shared publications - Maria Luisa Alcaide
Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
5 shared publications
Latest Publications
- 4 September 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
PREVALENCE AND SEVERITY OF STEATOTIC LIVER DISEASE IN WOMEN WITH AND WITHOUT HIV
Introduction: Steatotic liver disease (SLD) is highly prevalent in people with HIV (PWH) and is a major cause of morbidity and mortality in this population. However, it remains unclear whether SLD is influenced by HIV infection and whether the clinical management of PWH who have SLD should differ from non-HIV populations. Methods: Liver steatosis and fibrosis were assessed using vibration-controlled transient elastography (VCTE) among 1,580 women (1,117 with HIV; 463 without) enrolled in the Women’s Interagency HIV Study between 2013 and 2018. Steatosis was defined by a controlled attenuation parameter (CAP) ≥248 dB/m, and clinically significant fibrosis by liver stiffness ≥7.1 kPa. Participants were classified according to the AASLD diagnostic algorithm for SLD. Differences in fibrosis prevalence by HIV status were evaluated, and multivariable logistic regression was performed to identify factors associated with SLD and fibrosis, adjusting for age, ethnicity, BMI, alcohol use, diabetes, and smoking. Results: Prevalence of SLD was 740 of 1580 (47%) and did not differ by HIV serostatus. Most SLD was metabolic dysfunction-associated steatotic liver disease (MASLD; 629 of 740 [82%]). HIV infection was associated with higher odds of clinically significant fibrosis only among women with SLD (adjusted OR 1.48, 95% CI 1.01–2.16, p=0.04; HIV*SLD interaction among entire cohort p=0.03). Discussion: In this study, most SLD in women living with HIV is classified as MASLD. HIV infection is associated with higher odds of hepatic fibrosis only among those with SLD. Further work is needed to understand how HIV may potentiate fibrosis in the setting of SLD.
- 4 September 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
PREVALENCE AND SEVERITY OF STEATOTIC LIVER DISEASE IN WOMEN WITH AND WITHOUT HIV
Introduction: Steatotic liver disease (SLD) is highly prevalent in people with HIV (PWH) and is a major cause of morbidity and mortality in this population. However, it remains unclear whether SLD is influenced by HIV infection and whether the clinical management of PWH who have SLD should differ from non-HIV populations. Methods: Liver steatosis and fibrosis were assessed using vibration-controlled transient elastography (VCTE) among 1,580 women (1,117 with HIV; 463 without) enrolled in the Women’s Interagency HIV Study between 2013 and 2018. Steatosis was defined by a controlled attenuation parameter (CAP) ≥248 dB/m, and clinically significant fibrosis by liver stiffness ≥7.1 kPa. Participants were classified according to the AASLD diagnostic algorithm for SLD. Differences in fibrosis prevalence by HIV status were evaluated, and multivariable logistic regression was performed to identify factors associated with SLD and fibrosis, adjusting for age, ethnicity, BMI, alcohol use, diabetes, and smoking. Results: Prevalence of SLD was 740 of 1580 (47%) and did not differ by HIV serostatus. Most SLD was metabolic dysfunction-associated steatotic liver disease (MASLD; 629 of 740 [82%]). HIV infection was associated with higher odds of clinically significant fibrosis only among women with SLD (adjusted OR 1.48, 95% CI 1.01–2.16, p=0.04; HIV*SLD interaction among entire cohort p=0.03). Discussion: In this study, most SLD in women living with HIV is classified as MASLD. HIV infection is associated with higher odds of hepatic fibrosis only among those with SLD. Further work is needed to understand how HIV may potentiate fibrosis in the setting of SLD.
- Open Access
Use of Neuronal-Enriched Extracellular Vesicles to Distinguish Cognitive Impairment Levels and Sex Differences in People with HIV
Cognitive impairment still occurs despite well-controlled HIV but with milder symptoms. People with and without HIV have different neuronal protein changes that may differentiate the asymptomatic neurocognitive impairment (ANI) condition from normal cognition (NPN) and mild neurocognitive disorder (MND). Plasma neuronal-enriched extracellular vesicles (nEVs) were isolated from people with HIV (PWH) with NPN, ANI, or MND, and HIV seronegative controls with NPN (HIV−). Two different platforms were used to delineate protein patterns between sexes and cognitive conditions. When combining results from men and women, the nEV cargo in many cases showed little difference between cognitive conditions. However, when separated, there were different patterns between the sexes for some nEV cargo that distinguished the HIV− groups and HIV+ cognition groups. PWH with NPN had higher nEV toxic proteins compared to individuals without HIV. Women with HIV showed perfect separation between NPN and ANI with Aβ42 and NCAM-1 and perfect separation between ANI and MND with Aβ40 and NCAM-1. Men with HIV with MND had significantly higher NCAM-1 when compared to ANI, and lower GLRX when compared to NPN. This study shows distinct markers for different HIV cognitive categories, many of which differed between men and women.
Open AccessUse of Neuronal-Enriched Extracellular Vesicles to Distinguish Cognitive Impairment Levels and Sex Differences in People with HIV
Cognitive impairment still occurs despite well-controlled HIV but with milder symptoms. People with and without HIV have different neuronal protein changes that may differentiate the asymptomatic neurocognitive impairment (ANI) condition from normal cognition (NPN) and mild neurocognitive disorder (MND). Plasma neuronal-enriched extracellular vesicles (nEVs) were isolated from people with HIV (PWH) with NPN, ANI, or MND, and HIV seronegative controls with NPN (HIV−). Two different platforms were used to delineate protein patterns between sexes and cognitive conditions. When combining results from men and women, the nEV cargo in many cases showed little difference between cognitive conditions. However, when separated, there were different patterns between the sexes for some nEV cargo that distinguished the HIV− groups and HIV+ cognition groups. PWH with NPN had higher nEV toxic proteins compared to individuals without HIV. Women with HIV showed perfect separation between NPN and ANI with Aβ42 and NCAM-1 and perfect separation between ANI and MND with Aβ40 and NCAM-1. Men with HIV with MND had significantly higher NCAM-1 when compared to ANI, and lower GLRX when compared to NPN. This study shows distinct markers for different HIV cognitive categories, many of which differed between men and women.
- Open Access
- 18 August 2026
- Published by Springer Nature in AIDS and Behavior
- p. 1-10
Validation of an Extended Sexual Orientation and Gender Identity Measure in a Racially and Ethnically Diverse Cohort of People Living with or at Risk for HIV Infection
Despite becoming a routine part of clinical care, collection of sexual orientation and gender identity (SOGI) is not standardized, and common measures might not reflect the full range of LGBTQ+ experiences. In this study, we tested a novel expanded SOGI measure that addresses these concerns in a racially and ethnically diverse HIV cohort study. Participants ( N = 885) were randomized to complete either a common SOGI measure with fewer SOGI choices or an expanded SOGI measure with more response options. We assessed the sensitivity, specificity, positive and negative predictive values, and area under the curve of the receiver operating characteristic, comparing the common and expanded SOGI measures against a single LGBTQ+ identity question serving as the reference standard. We conducted the DeLong test to evaluate differences in the area under the curve between the common and expanded measures. The expanded measure had a sensitivity of 98.5% and a specificity of 81.2% for identifying LGBTQ+ participants. The common measure had a sensitivity of 99.2% and a specificity of 83.3%. The DeLong test yielded no statistically significant difference between these measures. This pattern persisted across most demographic groups, except for Black or African American participants, and participants in middle adulthood (41–60 years). There was no difference in participant discomfort in answering the questions in each measure. Collecting accurate SOGI information is crucial given persistent HIV-related healthcare disparities in LGBTQ+ populations.
- 18 August 2026
- Published by Springer Nature in AIDS and Behavior
- p. 1-10
Open AccessValidation of an Extended Sexual Orientation and Gender Identity Measure in a Racially and Ethnically Diverse Cohort of People Living with or at Risk for HIV Infection
Despite becoming a routine part of clinical care, collection of sexual orientation and gender identity (SOGI) is not standardized, and common measures might not reflect the full range of LGBTQ+ experiences. In this study, we tested a novel expanded SOGI measure that addresses these concerns in a racially and ethnically diverse HIV cohort study. Participants ( N = 885) were randomized to complete either a common SOGI measure with fewer SOGI choices or an expanded SOGI measure with more response options. We assessed the sensitivity, specificity, positive and negative predictive values, and area under the curve of the receiver operating characteristic, comparing the common and expanded SOGI measures against a single LGBTQ+ identity question serving as the reference standard. We conducted the DeLong test to evaluate differences in the area under the curve between the common and expanded measures. The expanded measure had a sensitivity of 98.5% and a specificity of 81.2% for identifying LGBTQ+ participants. The common measure had a sensitivity of 99.2% and a specificity of 83.3%. The DeLong test yielded no statistically significant difference between these measures. This pattern persisted across most demographic groups, except for Black or African American participants, and participants in middle adulthood (41–60 years). There was no difference in participant discomfort in answering the questions in each measure. Collecting accurate SOGI information is crucial given persistent HIV-related healthcare disparities in LGBTQ+ populations.
- 18 July 2026
- Published by Springer Nature in AIDS and Behavior
- p. 1-12
Implementation of State Prescription Drug Monitoring Program Mandatory Checking Requirements and Prescribed Opioid Analgesic Use Among Women With and Without HIV in The Women’s Interagency HIV Study: A Longitudinal Observational Study Using Staggered Adoption Difference-in-differences Analyses
Implementation of prescription drug monitoring programs requiring mandatory checking when prescribing or dispensing reduces opioid analgesic (OA) prescribing. OA receipt varies by individual-level factors, including HIV status. Mandatory prescription drug monitoring program checking requirements (MPDMPs) may exacerbate inequities if prompts trigger biased decision-making around clinical need for OAs. We examined whether MPDMP implementation was associated with changes in self-reported use of prescribed OAs among women and whether associations varied by HIV status. We conducted staggered adoption difference-in-differences analyses using 11 semi-annual data waves (2014–2019) from the Women’s Interagency HIV Study, a multisite observational cohort of women with and without HIV. Among 1,720 women, 71% had HIV; 61% were non-Hispanic Black. €The percentage of participants reporting prescribed OA use at baseline was comparable for women with HIV (16.5%) and without HIV (15.1%) but varied by race/ethnicity (non-Hispanic white 22.9%; non-Hispanic Black 13.6%; Hispanic 14.1%). In the adjusted model controlling for baseline age, race/ethnicity, education, HIV status, and census tract socioeconomic characteristics, MPDMP implementation was associated with a 3.6% percentage-point reduction in the probability prescribed OA use (average treatment effect on the treated = -0.036, 95% confidence interval − 0.060 to − 0.011). There was no significant evidence of variation by HIV status. MPDMPs reduce prescribed OA use in individuals. MPDMP implementation raises important questions about the role of provider bias in balancing reductions in overprescribing with maintaining access to OAs for those with special medical needs. Future research examining subgroups is needed to fully characterize MPDMP benefits and harms.
- 18 July 2026
- Published by Springer Nature in AIDS and Behavior
- p. 1-12
Implementation of State Prescription Drug Monitoring Program Mandatory Checking Requirements and Prescribed Opioid Analgesic Use Among Women With and Without HIV in The Women’s Interagency HIV Study: A Longitudinal Observational Study Using Staggered Adoption Difference-in-differences Analyses
Implementation of prescription drug monitoring programs requiring mandatory checking when prescribing or dispensing reduces opioid analgesic (OA) prescribing. OA receipt varies by individual-level factors, including HIV status. Mandatory prescription drug monitoring program checking requirements (MPDMPs) may exacerbate inequities if prompts trigger biased decision-making around clinical need for OAs. We examined whether MPDMP implementation was associated with changes in self-reported use of prescribed OAs among women and whether associations varied by HIV status. We conducted staggered adoption difference-in-differences analyses using 11 semi-annual data waves (2014–2019) from the Women’s Interagency HIV Study, a multisite observational cohort of women with and without HIV. Among 1,720 women, 71% had HIV; 61% were non-Hispanic Black. €The percentage of participants reporting prescribed OA use at baseline was comparable for women with HIV (16.5%) and without HIV (15.1%) but varied by race/ethnicity (non-Hispanic white 22.9%; non-Hispanic Black 13.6%; Hispanic 14.1%). In the adjusted model controlling for baseline age, race/ethnicity, education, HIV status, and census tract socioeconomic characteristics, MPDMP implementation was associated with a 3.6% percentage-point reduction in the probability prescribed OA use (average treatment effect on the treated = -0.036, 95% confidence interval − 0.060 to − 0.011). There was no significant evidence of variation by HIV status. MPDMPs reduce prescribed OA use in individuals. MPDMP implementation raises important questions about the role of provider bias in balancing reductions in overprescribing with maintaining access to OAs for those with special medical needs. Future research examining subgroups is needed to fully characterize MPDMP benefits and harms.
- Open Access
- 2 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6) , ofag346
High Prevalence of Hepatitis B in People With HIV in the MWCCS, 2018–2024
Background: This study aimed to examine the prevalence of hepatitis B virus (HBV) in people with HIV (PWH) undergoing contemporary antiretroviral therapy and people without HIV and to understand the risk factors in people with HIV/HBV coinfection. This retrospective cross-sectional study included 5238 participants with HIV or at risk for HIV acquisition across 13 US sites in the MACS/WIHS Combined Cohort Study (Multicenter AIDS Cohort Study / Women Interagency HIV Study) between January 2018 and December 2024. Methods: The primary outcome was the prevalence of HBV infection and HIV/HBV coinfection. We defined a positive HBsAg (surface antigen) as chronic HBV infection, a negative HBsAg and positive anti-HBV core antibody as recovered infection, and a negative HBsAg and negative anti-HBV core antibody as never infection. The prevalence of chronic and recovered HBV infection was described in different risk groups. Results: In this cohort, the overall prevalence of chronic HBV was 2.4%, and HIV/HBV coinfection was 3.0% among PWH. Current and prior HBV infection was more common in men, and the prevalence of prior HBV increased with age. As compared with the other 2 groups, PWH with chronic HBV infection had lower CD4+ T-cell counts (567 vs 651 and 689 cells/µL), CD4+ T-cell nadirs (210 vs 245 and 258 cells/µL), and HIV viral suppression rate (71.7% vs 82.3% and 83.7%). Among PWH who never had HBV infection, 40.6% lacked seroprotection against HBV. Conclusions: HBV is still prevalent in PWH. HBV coinfection was associated with lower CD4+ T-cell counts and viral suppression rate in PWH. The low seroprotection rate in those without HBV underscores the need for improved screening and immunization.
- 2 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6) , ofag346
Open AccessHigh Prevalence of Hepatitis B in People With HIV in the MWCCS, 2018–2024
Background: This study aimed to examine the prevalence of hepatitis B virus (HBV) in people with HIV (PWH) undergoing contemporary antiretroviral therapy and people without HIV and to understand the risk factors in people with HIV/HBV coinfection. This retrospective cross-sectional study included 5238 participants with HIV or at risk for HIV acquisition across 13 US sites in the MACS/WIHS Combined Cohort Study (Multicenter AIDS Cohort Study / Women Interagency HIV Study) between January 2018 and December 2024. Methods: The primary outcome was the prevalence of HBV infection and HIV/HBV coinfection. We defined a positive HBsAg (surface antigen) as chronic HBV infection, a negative HBsAg and positive anti-HBV core antibody as recovered infection, and a negative HBsAg and negative anti-HBV core antibody as never infection. The prevalence of chronic and recovered HBV infection was described in different risk groups. Results: In this cohort, the overall prevalence of chronic HBV was 2.4%, and HIV/HBV coinfection was 3.0% among PWH. Current and prior HBV infection was more common in men, and the prevalence of prior HBV increased with age. As compared with the other 2 groups, PWH with chronic HBV infection had lower CD4+ T-cell counts (567 vs 651 and 689 cells/µL), CD4+ T-cell nadirs (210 vs 245 and 258 cells/µL), and HIV viral suppression rate (71.7% vs 82.3% and 83.7%). Among PWH who never had HBV infection, 40.6% lacked seroprotection against HBV. Conclusions: HBV is still prevalent in PWH. HBV coinfection was associated with lower CD4+ T-cell counts and viral suppression rate in PWH. The low seroprotection rate in those without HBV underscores the need for improved screening and immunization.
- Open Access
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e041888
Associations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV
Background: Substance use is associated with cardiac disease, and women with HIV have a disproportionately high prevalence of substance use. However, the extent to which ongoing use of multiple substances relates to specific cardiovascular conditions in women with HIV and sociodemographically similar women without HIV (“at risk for HIV”) remains understudied. Methods: We measured left ventricular systolic dysfunction (LVSD) and diastolic dysfunction (LVDD), conditions that precede clinical heart failure, among 1651 participants of the multisite WIHS (Women's Interagency HIV Study). Using standardized echocardiography, we determined associations between the use of substances (stimulants, opioids, tobacco, alcohol, sedatives) reported at ≥2 biannual visits (“sustained use”) and left ventricular dysfunction. LVSD was defined as left ventricular ejection fraction <54%, and LVDD was considered in the absence of LVSD. Results: Most participants (75%) identified as non‐Hispanic Black, the average age was 49 years, 70% had HIV, and 4.9% had LVSD. In adjusted analysis, none of the sustained substance use categories were significantly associated with LVSD. Among women without LVSD, 6.6% had LVDD. The adjusted odds of LVDD were 6.82 times higher (95% CI, 5.47–8.50) among women with sustained methamphetamine/amphetamine use. Among women with HIV only, the adjusted odds for methamphetamine/amphetamine were 5.31 (95% CI, 4.21–6.70), and adjusted odds for cigarette use were 1.87 (95% CI, 1.39–2.52). Conclusions: In this national sample of women with and without HIV, sustained methamphetamine/amphetamine use had an especially strong association with LVDD that was independent of cigarette use. Routine assessment of methamphetamine/amphetamine use in vulnerable women may improve heart failure risk assessment.
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e041888
Open AccessAssociations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV
Background: Substance use is associated with cardiac disease, and women with HIV have a disproportionately high prevalence of substance use. However, the extent to which ongoing use of multiple substances relates to specific cardiovascular conditions in women with HIV and sociodemographically similar women without HIV (“at risk for HIV”) remains understudied. Methods: We measured left ventricular systolic dysfunction (LVSD) and diastolic dysfunction (LVDD), conditions that precede clinical heart failure, among 1651 participants of the multisite WIHS (Women's Interagency HIV Study). Using standardized echocardiography, we determined associations between the use of substances (stimulants, opioids, tobacco, alcohol, sedatives) reported at ≥2 biannual visits (“sustained use”) and left ventricular dysfunction. LVSD was defined as left ventricular ejection fraction <54%, and LVDD was considered in the absence of LVSD. Results: Most participants (75%) identified as non‐Hispanic Black, the average age was 49 years, 70% had HIV, and 4.9% had LVSD. In adjusted analysis, none of the sustained substance use categories were significantly associated with LVSD. Among women without LVSD, 6.6% had LVDD. The adjusted odds of LVDD were 6.82 times higher (95% CI, 5.47–8.50) among women with sustained methamphetamine/amphetamine use. Among women with HIV only, the adjusted odds for methamphetamine/amphetamine were 5.31 (95% CI, 4.21–6.70), and adjusted odds for cigarette use were 1.87 (95% CI, 1.39–2.52). Conclusions: In this national sample of women with and without HIV, sustained methamphetamine/amphetamine use had an especially strong association with LVDD that was independent of cigarette use. Routine assessment of methamphetamine/amphetamine use in vulnerable women may improve heart failure risk assessment.
- Open Access
- 31 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8) , ofaf414
Latent Healthcare Stigma Profiles and Their Association With Human Immunodeficiency Virus (HIV) Treatment and Care Outcomes Among Women With HIV in the United States: An Intersectional Analysis
Background: Stigma is a barrier to human immunodeficiency virus (HIV) care among women with HIV (WWH) in the United States (US). We estimated associations between latent stigma profiles and HIV outcomes among WWH in the Women's Interagency HIV Study. Methods: From 2018 to 2019, participants (N = 1407) completed semi-annual assessments on sociodemographics, substance use, HIV-related, anticipated, and race-related stigma in healthcare, and suboptimal antiretroviral therapy adherence (<95%), and underwent HIV RNA testing. Latent profile analysis and multinomial logistic regression were used to examine adjusted associations between profiles and several covariates. Structural equation modeling estimated longitudinal associations between profiles, suboptimal adherence, and viral nonsuppression (HIV-1 RNA ≥20 copies/mL). Results: We identified 3 profiles: high stigma (3%), low stigma (86%), and anticipated stigma (11%). Membership in the high stigma profile was greater for Black WWH who use drugs (adjusted odds ratio [aOR], 3.6 [95% confidence interval {CI}, 1.1–12.1]), non-Black WWH who use drugs (aOR, 4.8 [95% CI, 1.3–18]), and those who reported suboptimal adherence (aOR, 2.2 [95% CI, 1–4.8]), drug use (aOR, 2.6 [95% CI, 1.3–5.1]), noninjection drug use (aOR, 2.2 [95% CI, 1.1–4.4]), opioid use treatment (aOR, 4.07 [95% CI, 1.47–11.26]), depression (aOR, 5.8 [95% CI, 2.8–11.9]), stress (aOR, 1.09 [95% CI, 1.05–1.1]), and high post-traumatic stress disorder (aOR, 10.6 [95% CI, 4.3–25.7]). In the longitudinal model, suboptimal adherence was lowest for the low stigma profile and predicted future viral nonsuppression. Conclusions: Reducing stigma and integrating HIV, substance use, and mental health treatment is crucial for improving health outcomes among US WWH.
- 31 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8) , ofaf414
Open AccessLatent Healthcare Stigma Profiles and Their Association With Human Immunodeficiency Virus (HIV) Treatment and Care Outcomes Among Women With HIV in the United States: An Intersectional Analysis
Background: Stigma is a barrier to human immunodeficiency virus (HIV) care among women with HIV (WWH) in the United States (US). We estimated associations between latent stigma profiles and HIV outcomes among WWH in the Women's Interagency HIV Study. Methods: From 2018 to 2019, participants (N = 1407) completed semi-annual assessments on sociodemographics, substance use, HIV-related, anticipated, and race-related stigma in healthcare, and suboptimal antiretroviral therapy adherence (<95%), and underwent HIV RNA testing. Latent profile analysis and multinomial logistic regression were used to examine adjusted associations between profiles and several covariates. Structural equation modeling estimated longitudinal associations between profiles, suboptimal adherence, and viral nonsuppression (HIV-1 RNA ≥20 copies/mL). Results: We identified 3 profiles: high stigma (3%), low stigma (86%), and anticipated stigma (11%). Membership in the high stigma profile was greater for Black WWH who use drugs (adjusted odds ratio [aOR], 3.6 [95% confidence interval {CI}, 1.1–12.1]), non-Black WWH who use drugs (aOR, 4.8 [95% CI, 1.3–18]), and those who reported suboptimal adherence (aOR, 2.2 [95% CI, 1–4.8]), drug use (aOR, 2.6 [95% CI, 1.3–5.1]), noninjection drug use (aOR, 2.2 [95% CI, 1.1–4.4]), opioid use treatment (aOR, 4.07 [95% CI, 1.47–11.26]), depression (aOR, 5.8 [95% CI, 2.8–11.9]), stress (aOR, 1.09 [95% CI, 1.05–1.1]), and high post-traumatic stress disorder (aOR, 10.6 [95% CI, 4.3–25.7]). In the longitudinal model, suboptimal adherence was lowest for the low stigma profile and predicted future viral nonsuppression. Conclusions: Reducing stigma and integrating HIV, substance use, and mental health treatment is crucial for improving health outcomes among US WWH.
- 9 June 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (7) , ofaf340
Clinical and Health Care Resource Use Outcomes Associated With Resistance to Antiretroviral Therapy Among Veterans With HIV
Background: This study evaluated clinical and economic outcomes associated with antiretroviral therapy (ART) resistance among people with HIV (PWH) within a nationally representative database. Methods: Retrospective claims data were extracted from the Veterans Affairs Informatics and Computing Infrastructure. PWH receiving testing for resistance-associated mutations (RAMs) between 2003 and 2023 were categorized as resistant if they had ≥1 documented RAM in integrase strand transfer inhibitor, protease inhibitor, or reverse transcriptase genes. Results: Among 7746 veterans with interpretable resistance tests, 1875 had no detectable resistance, 4466 had ≥1 major or minor RAM (any RAM), and 1405 had ≥1 major RAM. The median CD4 count was highest for those without RAMs (357 cells/mm3) and lowest for those with major RAMs (285 cells/mm3). Opportunistic infections during the 1-year follow-up were present in 3.8% without RAMs as compared with >5% for both RAM groups. Hospitalizations were more frequent in the major RAM and any RAM cohorts vs the no resistance cohort (P < .001 for both). Total all-cause costs averaged $45 476 for those without RAMs as compared with $49 945 for those with any RAM and $48 392 for those with a major RAM. Among PWH initiating ART after resistance testing (n = 3522), those without RAMs had the longest persistence, while those with RAMs had shorter persistence (P < .0001). PWH prescribed ART at the time of resistance testing who had RAMs were most likely to switch to a regimen based on an integrase strand transfer inhibitor or protease inhibitor. Conclusions: In this real-world analysis, PWH with detectable resistance had lower CD4 counts, more frequent hospitalizations and opportunistic infections, greater economic costs, and increased discontinuation of ART.
- 9 June 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (7) , ofaf340
Clinical and Health Care Resource Use Outcomes Associated With Resistance to Antiretroviral Therapy Among Veterans With HIV
Background: This study evaluated clinical and economic outcomes associated with antiretroviral therapy (ART) resistance among people with HIV (PWH) within a nationally representative database. Methods: Retrospective claims data were extracted from the Veterans Affairs Informatics and Computing Infrastructure. PWH receiving testing for resistance-associated mutations (RAMs) between 2003 and 2023 were categorized as resistant if they had ≥1 documented RAM in integrase strand transfer inhibitor, protease inhibitor, or reverse transcriptase genes. Results: Among 7746 veterans with interpretable resistance tests, 1875 had no detectable resistance, 4466 had ≥1 major or minor RAM (any RAM), and 1405 had ≥1 major RAM. The median CD4 count was highest for those without RAMs (357 cells/mm3) and lowest for those with major RAMs (285 cells/mm3). Opportunistic infections during the 1-year follow-up were present in 3.8% without RAMs as compared with >5% for both RAM groups. Hospitalizations were more frequent in the major RAM and any RAM cohorts vs the no resistance cohort (P < .001 for both). Total all-cause costs averaged $45 476 for those without RAMs as compared with $49 945 for those with any RAM and $48 392 for those with a major RAM. Among PWH initiating ART after resistance testing (n = 3522), those without RAMs had the longest persistence, while those with RAMs had shorter persistence (P < .0001). PWH prescribed ART at the time of resistance testing who had RAMs were most likely to switch to a regimen based on an integrase strand transfer inhibitor or protease inhibitor. Conclusions: In this real-world analysis, PWH with detectable resistance had lower CD4 counts, more frequent hospitalizations and opportunistic infections, greater economic costs, and increased discontinuation of ART.